XML 27 R19.htm IDEA: XBRL DOCUMENT
v3.25.2

Stock Option and Grant Plan | 6 Months Ended
--- | ---
Jun. 30, 2025
Share-Based Payment Arrangement [Abstract] |
Stock Option and Grant Plan | 10. Stock option and grant plan 2019 equity incentive plan As of June 30, 2025, the Company had 16,235,272 shares reserved including 1,760,173 shares available for future issuance, pursuant to the Beam Therapeutics Inc. 2019 Equity Incentive Plan. Stock-based compensation expense recorded as research and development and general and administrative expenses in the condensed consolidated statements of operations and other comprehensive loss is as follows (in thousands):
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Research and development |  | $ | 14,832 |  |  | $ | 18,803 |  |  | $ | 30,565 |  |  | $ | 36,448 |
General and administrative |  |  | 9,535 |  |  |  | 12,801 |  |  |  | 20,484 |  |  |  | 24,437 |
Total stock-based compensation expense |  | $ | 24,367 |  |  | $ | 31,604 |  |  | $ | 51,049 |  |  | $ | 60,885 |
Stock options The following table provides a summary of stock option activity under the Company’s equity award plans:
|  | Number of options |  |  | Weighted average exercise price |
Outstanding at December 31, 2024 |  |  | 9,605,542 |  |  | $ | 38.62 |
Granted |  |  | 2,527,034 |  |  |  | 24.61 |
Exercised |  |  | (195,198 | ) |  |  | 12.68 |
Forfeited |  |  | (320,607 | ) |  |  | 44.06 |
Outstanding at June 30, 2025 |  |  | 11,616,771 |  |  |  | 35.87 |
Exercisable as of June 30, 2025 |  |  | 6,736,942 |  |  | $ | 40.93 |
The weighted-average grant date fair value per share of stock options granted in the six months ended June 30, 2025 was $17.60. As of June 30, 2025, there was $95.7 million of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average remaining vesting period of approximately 2.6 years. Restricted stock The Company issues shares of restricted common stock, including both restricted stock units and restricted stock awards. Restricted common stock issued generally vests over a period of two to four years. The following table summarizes the Company’s restricted stock activity:
|  | Shares |  |  | Weighted- average grant date fair value |
Unvested as of December 31, 2024 |  |  | 2,576,855 |  |  | $ | 36.98 |
Issued |  |  | 1,269,600 |  |  |  | 19.39 |
Vested |  |  | (688,359 | ) |  |  | 45.53 |
Forfeited |  |  | (272,784 | ) |  |  | 24.86 |
Unvested as of June 30, 2025 |  |  | 2,885,312 |  |  | $ | 28.35 |
At June 30, 2025, there was approximately $66.6 million of unrecognized stock-based compensation expense related to restricted stock that is expected to vest. These costs are expected to be recognized over a weighted-average remaining vesting period of approximately 2.7 years. 2019 employee stock purchase plan The Company issued 90,436 and 76,461 shares under the Beam Therapeutics Inc. 2019 Employee Stock Purchase Plan, or ESPP, during the six months ended June 30, 2025 and 2024, respectively. As of June 30, 2025, the Company had 3,674,600 shares available for issuance under the ESPP. Stock-based compensation recognized under the ESPP for the three and six months ended June 30, 2025 was $0.4 million and $0.7 million, respectively. The Company recognized stock-based compensation under the ESPP of $0.3 million and $0.6 million for the three and six months ended June 30, 2024, respectively.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration